Progressive muscle relaxation
What studies of progressive muscle relaxation found
At a glance, by condition
Long COVID: D Little or no difference
Based on the strongest evidence, the placebo trial (low certainty): 2 findings, all D.
9 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Studies found little or no difference with progressive muscle relaxation for long COVID. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- CMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- Progressive muscle relaxation · Long COVID is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Anxiety1 study · 31 people took part in progressive muscle relaxation Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (61 in all).
The randomised trial61 randomised · Following a 21-day intervention · 20 min daily sessions
Anxiety improved more than in the comparison group.
The evidence is very uncertain about the effect of progressive muscle relaxation on anxiety in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (61 in all)
See the 1 study
-
- People in the study
- 61 randomised
- Dose
- 20 min daily sessions
- Outcome
- general anxiety levels (as indicated by the Generalized Anxiety Disorders Scale-7) Generalized Anxiety Disorders Scale-7
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Depression1 study · 31 people took part in progressive muscle relaxation Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (61 in all).
The randomised trial61 randomised · Following a 21-day intervention · 20 min daily sessions
Depression improved more than in the comparison group.
The evidence is very uncertain about the effect of progressive muscle relaxation on depression in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (61 in all)
See the 1 study
-
- People in the study
- 61 randomised
- Dose
- 20 min daily sessions
- Outcome
- patient health (as assessed by the Patient Health Questionnaire-9) Patient Health Questionnaire-9
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Fatigue1 study · 31 people took part in progressive muscle relaxation Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (61 in all).
The randomised trial61 randomised · Following a 21-day intervention · 20 min daily sessions
Fatigue improved more than in the comparison group.
The evidence is very uncertain about the effect of progressive muscle relaxation on fatigue in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (61 in all)
See the 1 study
-
- People in the study
- 61 randomised
- Dose
- 20 min daily sessions
- Outcome
- fatigue
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Low mood or anxiety1 study · 31 people took part in progressive muscle relaxation Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (61 in all).
The randomised trial61 randomised · Following a 21-day intervention · 20 min daily sessions
Low mood or anxiety improved more than in the comparison group.
The evidence is very uncertain about the effect of progressive muscle relaxation on low mood or anxiety in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (61 in all)
See the 1 study
-
- People in the study
- 61 randomised
- Dose
- 20 min daily sessions
- Outcome
- GHQ-12 score General Health Questionnaire-12
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Sleep1 study · 31 people took part in progressive muscle relaxation Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (61 in all).
The randomised trial61 randomised · Following a 21-day intervention · 20 min daily sessions
Sleep improved more than in the comparison group.
The evidence is very uncertain about the effect of progressive muscle relaxation on sleep in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (61 in all)
See the 1 study
-
- People in the study
- 61 randomised
- Dose
- 20 min daily sessions
- Outcome
- sleep quality Pittsburgh Sleep Quality Index
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Cognition (brain fog)1 study · 20 people took part in progressive muscle relaxation Little or no difference D
Why this grade: Little or no difference, low certainty, from randomised trials: one trial of 60 people found no clear difference; a small benefit can't be ruled out.
The placebo trial60 randomised · nine 20-minute intervention sessions over three weeks · nine 20-minute intervention sessions over three weeks, three sessions per week on alternating days: Monday, Wednesday, and Friday
No clear difference in cognition (brain fog).
Progressive muscle relaxation may make little or no difference to cognition (brain fog) in long COVID. Little or no difference · low certainty D
- One trial of 60 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
Transcranial direct current stimulation-augmented cognitive training for post-COVID-19 cognition: A phase IIb randomized controlled trial (2026) preprint
- People in the study
- 60 randomised
- Dose
- nine 20-minute intervention sessions over three weeks, three sessions per week on alternating days: Monday, Wednesday, and Friday
- Outcome
- N-back task performance (untrained working memory), primary outcome, CT vs PMR at post-intervention
- Effect
- no clear difference
- Risk of bias
RoB 2: Low
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
Daily life and health overall
Overall symptoms1 study · 31 people took part in progressive muscle relaxation Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (61 in all).
The randomised trial61 randomised · Following a 21-day intervention · 20 min daily sessions
Overall symptoms improved more than in the comparison group.
The evidence is very uncertain about the effect of progressive muscle relaxation on overall symptoms in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (61 in all)
See the 1 study
-
- People in the study
- 61 randomised
- Dose
- 20 min daily sessions
- Outcome
- overall health (as measured by the General Health Questionnaire-12) General Health Questionnaire-12
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Daily functioning2 studies · 51 people took part in progressive muscle relaxation Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; 121 people in all; a small benefit can't be ruled out.
Randomised trials2 studies · 121 people with results
No clear difference in daily functioning.
The evidence is very uncertain about the effect of progressive muscle relaxation on daily functioning in long COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- 121 people in all; a small benefit can't be ruled out
See the 2 studies
-
- People in the study
- 61 randomised
- Dose
- 20 min daily sessions
- Outcome
- exercise capacity (6MWT) 6 min walking test
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
Transcranial direct current stimulation-augmented cognitive training for post-COVID-19 cognition: A phase IIb randomized controlled trial (2026) preprint
- People in the study
- 60 randomised
- Dose
- nine 20-minute intervention sessions over three weeks, three sessions per week on alternating days: Monday, Wednesday, and Friday
- Outcome
- Functional status (Post-COVID Functional Status Scale), CT vs PMR Post-COVID Functional Status Scale
- Effect
- no clear difference
- Risk of bias
RoB 2: Low
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
Quality of life1 study · 20 people took part in progressive muscle relaxation Little or no difference D
Why this grade: Little or no difference, low certainty, from randomised trials: one trial of 60 people found no clear difference; a small benefit can't be ruled out.
The placebo trial60 randomised · nine 20-minute intervention sessions over three weeks · nine 20-minute intervention sessions over three weeks, three sessions per week on alternating days: Monday, Wednesday, and Friday
No clear difference in quality of life.
Progressive muscle relaxation may make little or no difference to quality of life in long COVID. Little or no difference · low certainty D
- One trial of 60 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
Transcranial direct current stimulation-augmented cognitive training for post-COVID-19 cognition: A phase IIb randomized controlled trial (2026) preprint
- People in the study
- 60 randomised
- Dose
- nine 20-minute intervention sessions over three weeks, three sessions per week on alternating days: Monday, Wednesday, and Friday
- Outcome
- Health-related quality of life (PROPr score), CT vs PMR PROMIS-Preference (PROPr) score
- Effect
- no clear difference
- Risk of bias
RoB 2: Low
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
Side effects
Stopping because of side effects1 study
No serious AE were reported and no participant discontinued the intervention due to AE.
Transcranial direct current stimulation-augmented cognitive training for post-COVID-19 cognition: A phase IIb randomized controlled trial (2026)
All papers
- Transcranial direct current stimulation-augmented cognitive training for post-COVID-19 cognition: A phase IIb randomized controlled trial2026 · placebo trial · 60 randomised · preprint
- Effectiveness of Combined Pulmonary Rehabilitation and Progressive Muscle Relaxation in Treating Long-Term COVID-19 Symptoms: A Randomized Controlled Trial.2024 · randomised trial · 61 randomised
Summary
This randomized controlled trial asked whether adding progressive muscle relaxation (PMR) to pulmonary rehabilitation (PR) helps long-term COVID-19 symptoms. It included 61 post-COVID-19 patients who came to the hospital for pulmonary rehabilitation and randomly assigned them to PR only (group 1, 30 subjects) or PR with PMR (group 2, 31 subjects). The PR program lasted 21 days and included gradual aerobic conditioning, strength training, and breathing exercises. Group 2 received additional 20 min daily sessions of progressive muscle relaxation techniques; the PMR program lasted 21 days. Following a 21-day intervention, both groups had noteworthy improvements in lung function, exercise capacity, and sleep quality with statistical significance (p < 0.0001). Group 2 showed significant improvements in overall health (General Health Questionnaire-12), patient health (Patient Health Questionnaire-9), general anxiety levels (Generalized Anxiety Disorders Scale-7), and sleep quality (Pittsburgh Sleep Quality Index) with statistical significance (p < 0.0001), compared to group 1. The statistical analysis demonstrated no significant difference in exercise capacity improvement between group 1 and group 2 (p = 0.1711). The study showed no significant changes in functional capacity in both groups and did not show differences in functional capacity between the two groups. In Group 1, median FVC% increased from 71.50% to 76% post-intervention (p < 0.001), and mean 6MWT distance increased from 332.06 m to 366.60 m. In group 2, GHQ-12 scores reduced by a mean of 4.9 points, GAD-7 decreased by 4.9 points, and PSQI scores were reduced by 4.74 points. The text does not report side effects or withdrawals.
- Effectiveness of physical, psychological, and alternative interventions for post-COVID-19 condition: a systematic review.2026 · systematic review
Summary
This systematic review asked whether supervised physical, psychological and alternative non-pharmacological treatments help adults with post-COVID-19 condition. It included 27 randomized trials with 1,998 participants; trials were supervised and face-to-face and compared interventions with usual care, placebo/sham or active comparators. Interventions included cardiopulmonary rehabilitation, multimodal and unimodal exercise, CBT and lifestyle programmes, neuromodulation, oxygen therapies, acupuncture and balneotherapy. Intervention durations varied. The review reported that cardiopulmonary rehabilitation and multimodal exercise consistently improved cardiorespiratory fitness and walking capacity; CBT and lifestyle adjustments significantly reduced fatigue and subjective concentration complaints. Examples recorded: in 114 participants, CBT lowered CIS-fatigue by a between-group mean difference of −8.8 points (95% CI −11.9 to −5.8); in 70 participants, active HD-tDCS plus rehabilitation lowered MFIS total fatigue by a between-group difference of −14.03 points (95% CI −20.28 to −7.78). Findings for neuromodulation, complementary and oxygen therapies were heterogeneous, often showing no benefit over placebo. For example, HBOT did not produce significantly greater improvements than sham on any primary or secondary outcome. Side effects and withdrawals were not reported in the recorded data. The authors state that the evidence does not support definitive conclusions about the effectiveness of any intervention category.
- The Psychological and Physical Benefits of Progressive Muscle Relaxation in Chronic Respiratory Diseases: A Systematic Review.2025 · systematic review
Summary
This systematic review asked whether progressive muscle relaxation (PMR) affects psychological and physical outcomes in chronic respiratory disease. It searched PubMed, Scopus, Web of Science, MEDLINE, Cochrane, SpringerLink, and ClinicalTrials.gov and included 32 studies. Populations were adults with COPD, cystic fibrosis, COVID-19, asthma, pulmonary arterial hypertension, lung cancer, lung resection, or thoracic surgery; no ME/CFS data were recorded. PMR was given alone or with pursed-lip breathing, pulmonary rehabilitation, pulmonary telerehabilitation, biofeedback-assisted breathing, or other relaxation techniques. Examples of duration were 25 min twice daily for five consecutive days, 30 min daily for 5 days, 21 days, 6 weeks, four weeks, 7 days, and 12 weeks. Comparisons included control groups, PTR alone, PR alone, PLB alone, standard care, breathing exercises, music, or rest. Outcomes included anxiety, depression, fatigue, sleep quality, dyspnea, oxygen saturation, pulmonary function, quality of life, and exercise capacity. Reported changes included PSQI 10.80 to 4.0 in 60 COPD patients; PSQI 13.5 to 4.10 and 13.80 to 5.3 in 68 COPD patients; anxiety 14.2 to 7.6 and PSQI 10.5 to 5.2 in 79 COVID-19 patients; STAI 55.3 to 38.6 in 51 COVID-19 patients; anxiety 57.3 to 40.6 in 146 COVID-19 patients; HADS-A 9.45 to 6.82 and HADS-D 8.36 to 5.91 in 22 cystic fibrosis patients; FSS 46.75 to 24.66 in 91 COPD patients; SAS 58.1 to 49.7 in 130 PAH patients. The 6MWT increased by +43.6 m and +47.2 m with no significant difference between groups (p = 0.089); oxygen saturation and lung capacity were also reported as not significantly different. Side effects and withdrawals were not reported. The authors stated that evidence is limited by methodological variations and lack of long-term follow-up.
- Traditional, complementary and integrative medicine for fatigue post COVID-19 infection: A systematic review of randomized controlled trials.2024 · systematic review
Summary
This systematic review asked whether traditional, complementary and integrative medicine reduces fatigue after COVID-19. It included thirteen RCTs with 1632 participants; participants from eight RCTs were conducted in China. Searches ran to 12 April 2023. Trials compared herbal and Chinese medicine, probiotics/systemic enzymes, aromatherapy, neuro-meditation, progressive muscle relaxation, and other approaches with placebo, no treatment, or rehabilitation/conventional comparators. For Ludangshen oral liquid versus placebo, fatigue severity was MD -1.90 [-2.38, -1.42], P<0.001; fatigue disappearance RR 4.19 [2.06, 8.53], P<0.001; remission RR 2.04 [1.58, 2.63], P<0.001. Bufei Huoxue capsules versus placebo had MD -14.90 [-24.53, -5.27], P=0.02; Qingjin Yiqi granules plus TCM rehabilitation versus TCM rehabilitation had MD -0.48 [-0.50, -0.46], P<0.001. ADAPT-232/Chisan® versus placebo had MD -1.02 [-2.40, 0.36], P=0.15. Adverse events included abnormal liver function 4 with Bufei Huoxue and 2 with placebo; liver injury 1; diarrhea 1; excessive menstruation 1. None of the trials reported serious adverse events.